Characterization of β-catenin expression in canine osteosarcoma

Veterinary and Comparative Oncology

Volumn 9, Issue 1, 2011, Pages 65-73

  Stein, T J ^a   Holmes, K E ^a   Muthuswamy, A ^a   Thompson, V ^a   Huelsmeyer, M K ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Comparative oncology; Immunohistochemistry; Wnt signalling

Indexed keywords

BETA CATENIN; WNT PROTEIN;

ANIMAL; ANIMAL DISEASE; ARTICLE; BONE TUMOR; CELL NUCLEUS; CYTOPLASM; DISEASE MODEL; DOG; DOG DISEASE; EXON; FEMALE; GENETICS; HUMAN; MALE; METABOLISM; MUTATION; OSTEOSARCOMA; PATHOLOGY;

ANIMALS; BETA CATENIN; BONE NEOPLASMS; CELL NUCLEUS; CYTOPLASM; DISEASE MODELS, ANIMAL; DOG DISEASES; DOGS; EXONS; FEMALE; HUMANS; MALE; MUTATION; OSTEOSARCOMA; WNT PROTEINS;

CANIS FAMILIARIS;

EID: 79551716150     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2010.00236.x     Document Type: Article

References (30)

1. Polakis P. Wnt signaling and cancer. Genes and Development 2000; 14: 1837-1851.
2. Rubinfeld B, Souza B, Albert I, Muller O, Chamberlain SH, Masiarz FR, Munemitsu S and Polakis P. Association of the APC gene product with beta-catenin. Science 1993; 262: 1731-1734.
3. Rubinfeld B, Albert I, Porfiri E, Fiol C, Munemitsu S and Polakis P. Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science 1996; 272: 1023-1026.
4. Hajra KM and Fearon ER. Cadherin and catenin alterations in human cancer. Genes Chromosomes Cancer 2002; 34: 255-268.
5. Day TF, Guo X, Garret-Beal L and Yang Y. Wnt/β-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Developmental Cell 2005; 8: 739-750.
6. Hill TP, Spater D, Taketo MM, Birchmeier W and Hartmann C. Canonical Wnt/β-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Developmental Cell 2005; 8: 727-738.
7. Glass DA and Karsenty G. In vivo analysis of Wnt signaling in bone. Endocrinology 2007; 148: 2630-2634.
8. Haydon RC, Deyrup A, Ishikawa A, Heck R, Jiang W, Zhou L, Feng T, King D, Cheng H, Breyer B, Peabody T, Simon MA, Montag AG and He TC. Cytoplasmic and/or nuclear accumulation of the β-catenin protein is a frequent event in human osteosarcoma. International Journal of Cancer 2002; 102: 338-342.
9. Hoang BH, Kubo T, Healey JH, Sowers R, Mazza B, Yang R, Huvos AG, Meyers PA and Gorlick R. Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma. International Journal of Cancer 2004; 109: 106-111.
10. Guo Y, Rubin EM, Xie J, Zi X and Hoang BH. Dominant negative LRP5 decreases tumorigenicity and metastasis of osteosarcoma in an animal model. Clinical Orthopedics and Related Research 2008; 466: 2039-2045.
11. Kansara M, Tsang M, Kodjabachian L, Sims NA, Trivett MK, Ehrich M, Dobrovic A, Slavin J, Choong PF, Simmons PJ, Dawid IB and Thomas DM. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. Journal of Clinical Investigation 2009; 119: 837-851.
12. Selvarajah GT, Kirpensteijn J, van Wolferen ME, Rao NA, Fieten H and Mol JA. Gene expression profiling of canine osteosarcoma reveals genes associated with short and long survival times. Molecular Cancer 2009; 8: 72-89.
13. Cai Y, Mohseny AB, Karperien M, Hogendoorn PC, Zhou G and Cleton-Jansen AM. Inactive Wnt/β-catenin pathway in conventional high-grade osteosarcoma. Journal of Pathology 2010; 220: 24-33.
14. Cleton-Jansen AM, Anninga JK, Briaire-de Bruijn IH, Romeo S, Oosting J, Egeler RM, Gelderblom H, Taminiau AH and Hogendoorn PC. Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways. British Journal of Cancer 2009; 101: 1909-1918.
15. Dernell WS, Ehrhart NP, Straw RC and Vail DM. Tumors of the skeletal system. In: Withrow & MacEwen's Small Animal Clinical Oncology, 4th edn., SJ Withrow and DM Vail, eds., St. Louis, MO, Saunders, Elsevier, 2007: 540-582.
16. Thomas R, Wang HJ, Tsai PC, Langford CF, Fosmire SP, Jubala CM, Getzy DM, Cutter GR, Modiano JF and Breen M. Influence of genetic background on tumor karyotypes: evidence for breed-associated aberrations in canine appendicular osteosarcoma. Chromosome Research 2009; 17: 365-377.
17. De Maria R, Miretti S, Iussich S, Olivero M, Morello E, Bertotti A, Christensen JG, Levine RA, Buracco P and Di Renzo MF. Met oncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre-clinical model of human osteosarcoma. Journal of Pathology 2009; 218: 399-408.
18. Paoloni M, Davis S, Lana S, Withrow S, Sangiorgi L, Picci P, Hewitt S, Triche T, Meltzer P and Khanna C. Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. BMC Genomics 2009; 10: 625-637.
19. Paoloni M and Khanna C. Translation of new cancer treatments from pet dogs to humans. Nature Reviews Cancer 2008; 8: 147-156.
20. Beam SL, Rassnick KM, Moore AS and McDonough SP. An immunohistochemical study of cyclooxygenase-2 expression in various feline neoplasms. Veterinary Pathology 2003; 40: 496-500.
21. Looper JS, Malarkey DE, Ruslander D, Proulx D and Thrall DE. Epidermal growth factor receptor expression in feline oral squamous cell carcinoma. Veterinary and Comparative Oncology 2006; 4: 33-40.
22. Hoang BH, Kubo T, Healey JH, Yang R, Nathan SS, Kolb EA, Mazza B, Meyers PA and Gorlick R. Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-β-catenin pathway. Cancer Research 2004; 64: 2734-2739.
23. Crawford HC, Fingleton BM, Rudolph-Owen LA, Goss KJ, Rubinfeld B, Polakis P and Matrisian LM. The metalloproteinase matrilysin is a target of β-catenin transactivation in intestinal tumors. Oncogene 1999; 18: 2883-2891.
24. Tetsu O and McCormick F. β-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999; 398: 422-426.
25. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B and Kinzler KW. Identification of c-MYC as a target of the APC pathway. Science 1998; 281: 1509-1512.
26. Kim PJ, Plescia J, Clevers H, Fearon ER and Altieri DC. Survivin and molecular pathogenesis of colorectal cancer. Lancet 2003; 362: 205-209.
27. Marchenko ND, Marchenko GN, Weinreb RN, Lindsey JD, Kyshtoobayeva A, Crawford HC and Strongin AY. β-Catenin regulates the gene of MMP-26, a novel metalloproteinase expressed both in carcinomas and normal epithelial cells. International Journal of Biochemistry and Cell Biology 2004; 36: 942-956.
28. Fife RS, Rougraff BT, Proctor C and Sledge GW. Inhibition of proliferation and induction of apoptosis by doxycycline in cultured human osteosarcoma cells. Journal of Laboratory and Clinical Medicine 1997; 130: 530-534.
29. Cakir Y and Hahn KA. Direct action by doxycycline against osteosarcoma cell proliferation and collagenase (MMP-1) activity in vitro. In Vivo 1999; 13: 327-331.
30. Segditsas S and Tomlinson I. Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene 2006; 25: 7531-7537.